CRBP
$9.63
Corbus Pharmaceuticals Holdings, Inc., a clinical stage company, develops and commercializes therapeutics for cancer and obesity.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Corbus Pharmaceuticals Holdings, Inc., a clinical stage company, develops and commercializes therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to rel...
Recent News
How Much Upside is Left in Corbus Pharmaceuticals (CRBP)? Wall Street Analysts Think 318.33%
The mean of analysts' price targets for Corbus Pharmaceuticals (CRBP) points to a 318.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Corbus Pharmaceuticals: Q4 Earnings Snapshot
NORWOOD, Mass. AP) — Corbus Pharmaceuticals Holdings Inc. CRBP) on Monday reported a loss of $20.6 million in its fourth quarter.
Corbus Pharmaceuticals Touts “Catalyst-Rich” 2026 With CRB-701 and CRB-913 Data Readouts Ahead
Corbus Pharmaceuticals (NASDAQ:CRBP) outlined a “catalyst-rich” 2026 at Oppenheimer’s 36th Annual Healthcare Conference, with Chief Executive Officer Yuval Cohen highlighting upcoming mid-year and late-year data readouts for the company’s two clinical-stage programs: CRB-701, a Nectin-4 antibody-dru
While hedge funds own 24% of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP), retail investors are its largest shareholders with 46% ownership
Key Insights The considerable ownership by retail investors in Corbus Pharmaceuticals Holdings indicates that they...
Corbus Pharmaceuticals Reports Phase 1a Obesity Drug Data Showing Weight Loss
Corbus Pharmaceuticals Holdings (CRBP) said Thursday it completed a phase 1a study of oral obesity d